<DOC>
	<DOCNO>NCT00141518</DOCNO>
	<brief_summary>The primary objective study collect health economic data depict initial level natural progression time resource usage , Parkinson 's disease ( PD ) -related cost , health relate quality life ( HRQoL ) cohort advance PD patient treat Duodopa ( levodopa-carbidopa intestinal gel formulation ) , one-third Duodopa-na√Øve prior start study .</brief_summary>
	<brief_title>Long-term Study Duodopa ( Levodopa/Carbidopa ) Advanced Parkinson 's : Health Outcomes &amp; Net Economic Impact</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Advanced idiopathic Parkinson 's disease Other disease might influence compliance participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Health economics , Quality life</keyword>
</DOC>